Genome-wide Association Studies of Antidepressant Class Response and Treatment-resistant Depression
Overview
Public Health
Authors
Affiliations
The "antidepressant efficacy" survey (AES) was deployed to > 50,000 23andMe, Inc. research participants to investigate the genetic basis of treatment-resistant depression (TRD) and non-treatment-resistant depression (NTRD). Genome-wide association studies (GWAS) were performed, including TRD vs. NTRD, selective serotonin reuptake inhibitor (SSRI) responders vs. non-responders, serotonin-norepinephrine reuptake inhibitor (SNRI) responders vs. non-responders, and norepinephrine-dopamine reuptake inhibitor responders vs. non-responders. Only the SSRI association reached the genome-wide significance threshold (p < 5 × 10): one genomic region in RNF219-AS1 (SNP rs4884091, p = 2.42 × 10, OR = 1.21); this association was also observed in the meta-analysis (13,130 responders vs. 6,610 non-responders) of AES and an earlier "antidepressant efficacy and side effects" survey (AESES) cohort. Meta-analysis for SNRI response phenotype derived from AES and AESES (4030 responders vs. 3049 non-responders) identified another genomic region (lead SNP rs4955665, p = 1.62 × 10, OR = 1.25) in an intronic region of MECOM passing the genome-wide significance threshold. Meta-analysis for the TRD phenotype (31,068 NTRD vs 5,714 TRD) identified one additional genomic region (lead SNP rs150245813, p = 8.07 × 10, OR = 0.80) in 10p11.1 passing the genome-wide significance threshold. A stronger association for rs150245813 was observed in current study (p = 7.35 × 10, OR = 0.79) than the previous study (p = 1.40 × 10, OR = 0.81), and for rs4955665, a stronger association in previous study (p = 1.21 × 10, OR = 1.27) than the current study (p = 2.64 × 10, OR = 1.21). In total, three novel loci associated with SSRI or SNRI (responders vs. non-responders), and NTRD vs TRD were identified; gene level association and gene set enrichment analyses implicate enrichment of genes involved in immune process.
Koch E, Jurgenson T, Einarsson G, Mitchell B, Harder A, Garcia-Marin L Res Sq. 2025; .
PMID: 39764137 PMC: 11703334. DOI: 10.21203/rs.3.rs-5418279/v1.
Liu C, Gershon E Transl Psychiatry. 2024; 14(1):502.
PMID: 39719446 PMC: 11668880. DOI: 10.1038/s41398-024-03195-1.
The genetics of severe depression.
Franklin C, Achtyes E, Altinay M, Bailey K, Bhati M, Carr B Mol Psychiatry. 2024; 30(3):1117-1126.
PMID: 39406997 DOI: 10.1038/s41380-024-02731-1.
Genetic determinants of antidepressant and antipsychotic drug response.
Stassen H, Bachmann S, Bridler R, Cattapan K, Hartmann A, Rujescu D Eur Arch Psychiatry Clin Neurosci. 2024; .
PMID: 39379546 DOI: 10.1007/s00406-024-01918-5.
Schiele M, Crespo Salvador O, Lipovsek J, Schwarte K, Schlosser P, Zwanzger P Int J Neuropsychopharmacol. 2024; 27(11).
PMID: 39367879 PMC: 11558245. DOI: 10.1093/ijnp/pyae045.